Detection of T790M Gefitinib Resistance Mutation in EGFR using the BEAMing method
| Project/Area Number |
20890299
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (Start-up)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | Research Institute, Osaka Medical Center for Cancer and Cardiovascular Disaeses |
|---|
Principal Investigator |
TANIGUCHI Kazuya Research Institute, Osaka Medical Center for Cancer and Cardiovascular Disaeses, 研究所, 研究員 (70463289)
|
|---|
| Project Period (FY) |
2008 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥3,302,000 (Direct Cost: ¥2,540,000、Indirect Cost: ¥762,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥1,742,000 (Direct Cost: ¥1,340,000、Indirect Cost: ¥402,000)
|
|---|
| Keywords | 非小細胞肺癌 / ゲフィチニブ / EGFR / 抗癌剤耐性 / 遺伝子変異 / 遺伝子診断 / 分子標的薬 |
|---|
| Research Abstract |
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib or erlotinib, are effective therapies for non-small cell lung cancer (NSCLC) patients with primary EGFR mutations. However, most patients who initially respond to treatment with these drugs will develop resistance to EGFR TKIs. A secondary EGFR T790M mutation is reported to correlate with acquired resistance. We examined the T790M mutation in primary tumors with BEAMing (beads, emulsion, amplification, magnetic), which is the most sensitive technique to detect minor mutated alleles. Currently, we can detect point mutation at the level of 1/10,000 using an improved version of the BEAMing. We detected T790M mutant alleles in NSCLCs in 20 out of 270 NSCLCs with primary EGFR mutations. The detection of small fraction of T790M mutant alleles may be useful for predicting resistance of NSCLCs to TKIs.
|
Report
(3 results)
Research Products
(13 results)
